Dr GEOFFROIS Lionnel

Fiche personne

Coordonnées

Institut de Cancérologie de Lorraine
Avenue de Bourgogne
54511 VANDOEUVRE-LES-NANCY Cedex
FRANCE

03 83 59 84 61

Territoire

Lorraine

Statut

Hospitalier

Affiliation

Institut de cancérologie de Lorraine (ICL)

Équipes/plateformes

Oncologie médicale

Recherche

Expertises :
- Clinique:Oncologie Médicale

Projets

Suivi personnalisé de l'ADN circulant dans les mélanomes cutanés opérés de stades III et IV

2021 - Porteur du projet : Dr GEOFFROIS Lionnel

Publications

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Mirghani H, Aupérin A, Even C, Larive A, Fayette J, Geoffrois L, Clatot F, Calderon B, Tao Y, Nguyen F, Fabiano E, Kreps S, Gaultier AL, Bidault F, Puech J, Morin B, Picavet L, Tartour E, Ben Hariz A, Chevrot M, Monard L, Veyer D, Badoual C, Péré H, Blanchard P

J Clin Oncol. 2026 01 22;:JCO2500835

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 tria

Bourhis J, Aupérin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y

Lancet. 2025 12 22;:

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

Flippot R, Vano YA, Dalban C, Beuselinck B, Fléchon A, Meylan M, Pouessel D, Bougoüin A, Sautes-Fridman C, Gravis G, Chaput N, Oudard S, Desnoyer A, Laguerre B, Chouaib S, Barthelemy P, Borchiellini D, Carril-Ajuria L, Gross-Goupil M, Fridman WH, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Chabaud S, Escudier B, Rioux-Leclercq N, Albiges L,

Eur Urol. 2025 11 11;:

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Skowron F, Mouret S, Seigneurin A, Montaudié H, Maubec E, Grange F, Quereux G, Célérier P, Amini-Adle M, Dalac-Rat S, De Quatrebarbes J, Zehou O, Safia A, Muller P, Modiano P, Misery L, Litrowski N, Brunet-Possenti F, Mortier L, Bens G, Hervieu A, Leduc N, Jouary T, Lesage C, Beneton N, Le Corre Y, Geoffrois L, Thomas-Beaulieu D, Hainaut E, Charles J, Leccia MT

Ann Dermatol Venereol. 2025 09 4;152(4):103418

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial: TPEx versus EXTREME as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L, ,Bourhis J, Guigay J, Bonastre J

Value Health. 2025 08 21;:

The UNI-AJA Project: A Feasibility Study Based on Real-World Data in French Adolescents and Young Adults with Cancer.

Desandes E, Diatchenko A, Crochet H, André N, Blay JY, Gaspar N, Geoffrois L, Heinrich S, Kubicek P, Laurence V, Leblond P, Lervat C, Molimard L, Poirée M, Salomon M, Serre J, Toulmonde M, Varlet P, Durand T, Ducimetière F, Marec-Berard P

J Adolesc Young Adult Oncol. 2025 07 14;:

First-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real-World Study.

Simon A, Abdeddaim C, Nguyen D, Gallet P, Peiffert D, Lambert A, Geoffrois L

Head Neck. 2025 06 10;:

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.

Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P

World J Urol. 2025 01 2;43(1):54

Central nervous system complications of immune checkpoint inhibitors: a comprehensive review.

Lopes S, Pabst L, Bahougne T, Barthelemy P, Guitton R, Didier K, Geoffrois L, Granel-Brocard F, Mennecier B, Mascaux C, Kremer S, Collongues N

Crit Rev Oncol Hematol. 2024 12 12;:104595

13-year survival oligometastatic Merkel cell carcinoma: a case report.

Trampetti I, Faivre JC, Geoffrois L, Gehin W, Renard S

J Med Case Rep. 2024 09 18;18(1):455

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S

J Clin Oncol. 2024 08 21;:JCO2301960

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.

Guigay J, Le Caer H, Ferrand FR, Geoffrois L, Saada-Bouzid E, Fayette J, Sire C, Cupissol D, Blot E, Guillet P, Pavillet J, Bozec L, Capitain O, Rolland F, Debourdeau P, Pointreau Y, Falandry C, Lopez S, Coutte A, Chatellier T, Dalloz P, Ortholan C, Michel C, Lacas B, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A,

Lancet Healthy Longev. 2024 05 14;:

Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.

Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Tantot F, Chaput N, Naigeon M, Teixeira M, Escudier B, Flippot R, Albiges L

Eur J Cancer. 2024 02 3;201:113589

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity.

Marret G, Temam S, Kamal M, Even C, Delord JP, Hoffmann C, Dolivet G, Malard O, Fayette J, Capitain O, Vergez S, Geoffrois L, Rolland F, Zrounba P, Laccourreye L, Saada-Bouzid E, Aide N, Bénavent V, Klijianenko J, Lamy C, Girard E, Vacher S, Masliah-Planchon J, de Koning L, Puard V, Borcoman E, Jimenez M, Bièche I, Gal J, Le Tourneau C

Sci Rep. 2023 12 18;13(1):22524

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.

de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L

J Immunother Cancer. 2023 11;11(11):

NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).

Fayette J, Even C, Digue L, Geoffrois L, Rolland F, Cupissol D, Guigay J, Le Tourneau C, Dillies AF, Zanetta S, Bozec L, Borel C, Couchon-Thaunat S, Costes-Martineau V, Sudaka-Bahadoran A, Jallut I, Garic F, Lardy-Cleaud A, Chabaud S

BMJ Oncol. 2023 10 30;2(1):e000065

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.

Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G

Eur Urol Oncol. 2023 10 7;:

Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.

Baudry E, Naoun N, Auclin E, Saldana C, Barthelemy P, Geoffrois L, Thibault C, de Vries-Brilland M, Borchiellini D, Maillet D, Hirsch L, Vauchier C, Carril-Ajuria L, Colomba E, Bernard-Tessier A, Escudier B, Flippot R, Albigès L

Eur J Cancer. 2023 08 18;193:113292

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE

J Clin Oncol. 2023 06 27;:JCO2202887

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.

Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL

BMC Cancer. 2023 06 16;23(1):554

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.

Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C

Eur J Cancer. 2023 01 13;182:66-76

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J

Eur J Cancer. 2023 01 9;183:24-37

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.

Saint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M

Eur J Cancer. 2022 07 18;173:105-112

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.

Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P

Eur Urol Oncol. 2022 07 16;:

Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L

Clin Genitourin Cancer. 2022 07 10;:

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Loriot Y, Texier M, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K

Eur Urol. 2022 05 19;:

Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.

Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P

Support Care Cancer. 2022 Apr 29;:

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C,

Clin Genitourin Cancer. 2021 Sep 8;:

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Oudard S, Laguerre B, Gross-Goupil M, Bernhard JC, Colas S, Albiges L, Lebret T, Treluyer JM, Timsit MO, Escudier B

Eur Urol. 2021 Jun 26;:

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.

Courcier J, Dalban C, Laguerre B, Ladoire S, Barthélémy P, Oudard S, Joly F, Gravis G, Chevreau C, Geoffrois L, Deluche É, Rolland F, Topart D, Culine S, Négrier S, Mahammedi H, Tantot F, Jamet A, Escudier B, Flippot R, Albigès L

Eur Urol. 2021 Jun 5;:

Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.

Abu-Shama Y, Salleron J, Carsuzaa F, Sun XS, Pflumio C, Troussier I, Petit C, Caubet M, Beddok A, Calugaru V, Servagi-Vernat S, Castelli J, Miroir J, Krengli M, Giraud P, Romano E, Khalifa J, Doré M, Blanchard N, Coutte A, Dupin C, Sumodhee S, Tao Y, Roth V, Geoffrois L, Toussaint B, Nguyen DT, Faivre JC, Thariat J

Cancers (Basel). 2021 May 17;13(10):

Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.

Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, Hennequin C, Morgans AK, Geoffrois L, Limat S, Thiery-Vuillemin A, Nerich V

Clin Genitourin Cancer. 2021 Apr 5;:

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phas

Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R, ,,

Lancet Oncol. 2021 Mar 5;:

Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.

Pflumio C, Thomas J, Salleron J, Faivre JC, Borel C, Dolivet G, Sastre-Garau X, Geoffrois L

Oncol Rep. 2021 Jan 7;:

Factors associated with under-reporting of head and neck squamous cell carcinoma in cause-of-death records: A comparative study of two national databases in France from 2008 to 2012.

Even C, Sagaon Teyssier L, Pointreau Y, Temam S, Huguet F, Geoffrois L, Schwarzinger M,

PLoS One. 2021 ;16(2):e0246252

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.

Albiges L, Fléchon A, Chevreau C, Topart D, Gravis G, Oudard S, Tourani JM, Geoffrois L, Meriaux E, Thiery-Vuillemin A, Barthélémy P, Ladoire S, Laguerre B, Perrot V, Billard A, Escudier B, Gross-Goupil M

Eur J Cancer. 2020 Nov 27;142:102-111

A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.

Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, Senesse P,

Am. J. Clin. Nutr.. 2020 Sep 16;:

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J

Lancet Oncol.. 2020 Aug 3;:

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L

Eur. J. Cancer. 2020 Jul 9;136:76-83

Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review.

Lambert A, Salleron J, Kieffer A, Raymond P, Geoffrois L, Gavoille C

Bull Cancer. 2020 Jun 5;:

Assessment of patient knowledge and completion of advance directives in oncodermatology.

Melgar E, Escobar GF, Granel-Brocard F, Remen T, Marzouki-Zerouali A, Geoffrois L, Martin H, Schoeffler A, Schmutz JL, Bursztejn AC

Br. J. Dermatol.. 2020 May 30;:

Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.

Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, Bardet E, Calais MH, Garaud P, Calais G

Eur. J. Cancer. 2020 May 23;133:86-93

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B,

Eur. J. Cancer. 2020 Mar 5;129:107-116

Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Werle P, Balssa L, Geoffrois L, Leblanc L, Albigès L, di Nunno V, Bensalah K, Ladoire S, Gravis G, Barthélémy P

Eur. Urol.. 2020 Jan 3;:

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T

Oral Oncol.. 2019 Aug 23;97:82-91

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L

J. Clin. Oncol.. 2019 Jun 13;:JCO1802218

Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort study.

Pflumio C, Troussier I, Sun XS, Salleron J, Petit C, Caubet M, Beddok A, Calugaru V, Servagi-Vernat S, Castelli J, Miroir J, Krengli M, Giraud P, Romano E, Khalifa J, Doré M, Blanchard N, Coutte A, Dupin C, Sumodhee S, Pointreau Y, Patel S, Rehailia-Blanchard A, Catteau L, Bensadoun RJ, Tao Y, Roth V, Geoffrois L, Faivre JC, Thariat J

Eur. J. Cancer. 2019 Feb 28;111:69-81

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Negrier S, Chevreau CM, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Tantot F, Escudier B, Albiges L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii306

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap).

Negrier S, Rioux-Leclercq N, Ravaud A, Gravis G, Geoffrois L, Chevreau CM, Rolland F, Blanc E, Segura-Ferlay C, Perol D, Gross Goupil M, Dermeche S, Flechon A, Albiges L, Escudier B

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii307

Accelerated mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma.

Serre D, Salleron J, Husson M, Leroux A, Gilson P, Merlin JL, Geoffrois L, Harlé A

Oncotarget. 2018 Aug 14;9(63):32232-32237

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J

J. Clin. Oncol.. 2018 Jul 17;:JCO2017762591

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B

N. Engl. J. Med.. 2018 Jun 3;:

[Advances in the management of cervical lymphadenopathies of unknown primary with intensity modulated radiotherapy: Doses and target volumes].

Troussier I, Klausner G, Blais E, Giraud P, Lahmi L, Pflumio C, Faivre JC, Geoffrois L, Babin E, Morinière S, Maingon P, Thariat J

Cancer Radiother. 2018 May 3;:

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K

Eur. J. Cancer. 2017 12;87:140-146

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH

Ann. Oncol.. 2017 Oct;28(10):2526-2532

Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.

Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J

Oral Oncol.. 2017 Aug;71:61-66

Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ

Ann. Oncol.. 2017 Feb;:

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607

Long-term update of the 24954 EORTC phase III trial on larynx preservation.

Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Grégoire V,

Eur. J. Cancer. 2016 Sep;65:109-12

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M

Eur. J. Cancer. 2016 Jul;62:28-35

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S

Eur. J. Cancer. 2016 Feb;54:69-74

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R

Lancet Oncol. 2015 Jan;16(1):76-86

[Not Available].

Gimel P, Gross-Goupil M, Geoffrois L, Guillot A, Chevreau C, Deville J, Falkowski S, Boyle H, Baciuchka M, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Amela Y, Abadie S, Mahi N, Oudard S

Prog. Urol.. 2014 Nov;24(13):821

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Flechon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Miclea JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP

Ann Oncol. 2014 Sep;25(9):1775-82

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, Delva R, Eymard JC, Rolland F, Houede N, Laplanche A, Burcoveanu D, Culine S

Ann Oncol. 2014 May;25(5):987-91

[Contribution of an emergency dermatology consultation in a French cancer centre].

Reigneau M, Granel-Brocard F, Geoffrois L, Poreaux C, Peiffert D, Cuny JF, Bursztejn AC, Waton J, Schmutz JL, Barbaud A

Ann Dermatol Venereol. 2014 May;141(5):375-8

[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC].

Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Auperin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guily J, Bourhis J

Bull Cancer. 2013 Oct;100(10):983-97

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.

Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J

Oral Oncol. 2013 Jun;49(6):482-91

[Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].

Voilliot-Trotot C, Granel-Brocard F, Geoffrois L, Trechot P, Nguyen-Thi P, Schmutz JL, Barbaud A

Ann Dermatol Venereol. 2013 May;140(5):353-62

Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E

J Clin Oncol. 2013 Mar 1;31(7):853-9

Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).

Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrois L, Finetti P, Giraud P, Racadot S, Moriniere S, Sudaka A, Van Obberghen-Schilling E, Milano G

Clin Cancer Res. 2012 Sep 15;18(18):5123-33

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP

Ann. Oncol.. 2012 Aug;23(8):2153-61

Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture.

Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, Veracini L, Francoual M, Formento JL, Dassonville O, De Raucourt D, Geoffrois L, Giraud P, Racadot S, Moriniere S, Milano G, Van Obberghen-Schilling E

Clin Cancer Res. 2012 Mar 1;18(5):1313-22

[Evaluation of information about prophylactic treatment and management of hand-foot reactions caused by antiangiogenic therapies].

Guyot-Caquelin P, Geoffrois L, Barbaud A, Trechot P, Schmutz JL, Granel-Brocard F

Ann Dermatol Venereol. 2011 Aug-Sep;138(8-9):565-71

Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial.

Bourhis J, Lapeyre M, Tortochaux J, Lusinchi A, Etessami A, Ducourtieux M, Geoffrois L, Domenge C, Verrelle P, Wibault P, Janot F, Temam S, Blanchard P, Tao YG, Auperin A

Radiother Oncol. 2011 Jul;100(1):56-61

[Metastatic paraganglioma. Answer to May e-quid].

Oldrini G, Geoffrois L, Olivier P, Henrot P, Blum A

J Radiol. 2011 Jul-Aug;92(7-8):739-43.

Management of patients with head and neck tumours presenting at diagnosis with a synchronous second cancer at another anatomic site.

Graff P, Schipman B, Desandes E, Mecellem H, Toussaint B, Cortese S, Marchal F, Kaminsky MC, Geoffrois L, Peiffert D

Clin Oncol (R Coll Radiol). 2011 Apr;23(3):174-81

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB

J Natl Cancer Inst. 2009 Feb 4;101(3):142-52

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge

Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P

Support Care Cancer. 2008 Sep;16(9):1017-23

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors

Theodore C, Chevreau C, Yataqhene Y, Fizazi K, Delord JP, Lotz JP, Geoffrois L, Kerbrat P, Bui V, Flechon A

Ann Oncol. 2008 Aug;19(8):1465-9

Endoscopic surgery reveals that woodworkers' adenocarcinomas originate in the olfactory cleft

Jankowski R, Georgel T, Vignaud JM, Hemmaoui B, Toussaint B, Graff P, Geoffrois L, Henrot P, Kaminsky MC

Rhinology. 2007 Dec;45(4):308-14.

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T9313P).

Culine S, Kerbrat P, Kramar A, Theodore C, ChevreauU C, Geoffrois L, Bui NB, Peny J, Caty A, Delva R, Biron P, Fizazi K, Bouzy J, Droz JP

Ann Oncol. 2007 May;18(5):917-24

Gemcitabine and cisplatin after radical bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centres.

Flechon A, Fizazi K, Gourgou-Bourgade S, Theodore C, Beuzeboc P, Geoffrois L, Mottet N, Chevreau C, Culine S

Anticancer Drugs. 2006 Jul;17(6):705-8.

Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial.

Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M, Benhamou E

J Clin Oncol. 2006 Jun 20;24(18):2873-8.